English | 简体中文 | 繁體中文 | 한국어 | 日本語
2023年9月12日 21時22分
Share:
    

Source: Ad Scientiam
Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot

PARIS, FRANCE, 2023年9月12日 - (亞太商訊) - Ad Scientiam, a global leader in digital biomarkers, has announced a partnership with Sanofi to launch MS-DETECT, an international, multicenter, longitudinal study. MS-DETECT aims to evaluate the ability of MSCopilot(R), a medical software device, to detect early signs of disability worsening in people with multiple sclerosis (PwMS). The study will draw upon Ad Scientiam's expertise in MS and is financially supported by Sanofi.

Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination and subsequent neurodegeneration. Current clinical evaluation of PwMS relies mainly on the Expanded Disability Status Scale (EDSS), which has several limitations. To improve on these assessments, Ad Scientiam has developed MSCopilot(R), a software medical device that addresses four dimensions: ambulation/mobility, upper extremity function, cognition, and low-contrast visual acuity.

MS-DETECT's main objective is to determine MSCopilot(R)'s ability to identify subtle and early disability worsening. This will be performed by evaluating MSCopilot(R) individual and/or composite scores as compared to the Multiple Sclerosis Functional Composite (MSFC) and the EDSS.

"MS-DETECT is a pioneering large-scale longitudinal study that explores digital biomarkers for the early detection of disease progression. This study will provide important data to both clinicians and people living with MS," according to Dr. Saad Zinai, Chief Medical Officer at Ad Scientiam.

"Disability worsening in MS has been recently redefined and we now know that this progression can occur independently of relapses. With MS-DETECT, we have an opportunity to develop a digital solution to help detect and monitor the effects of smoldering disease, and evolve treatment goals for MS patients," explains Su-Peing Ng, Global Head of Medical Affairs - Specialty Care at Sanofi.

The study also aims to assess the MSCopilot(R) performance, safety, usability and satisfaction with the solution.

"Disease progression can be hard to detect in routine practice. I believe these novel digital biomarkers are key to help clinicians make appropriate treatment decisions and, ultimately, improve patients' care," said Prof. Patrick Vermersch (Lille, France), Coordinating Investigator and Chairman of the Study Steering Committee.

The MS-DETECT study will include 314 PwMS and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France. Several investigative sites have already been initiated in North America and Europe and first patients are expected to participate in the study during Q3 2023.
Check our LinkedIn, Facebook, Instagram pages or visit adscientiam.com

Contact Information
Saad Zinai
Chief Medical Officer
szinai@adscientiam.com
+33768008666

Matthieu Lamy
President
mlamy@adscientiam.com
+33768008666

Topic: Press release summary
Source: Ad Scientiam


https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Ad Scientiam Related News
Sept 12, 2023 20:00 HKT/SGT
Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575